JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Elenco Azioni・Savara Inc

Savara Inc

Chiusa

SettoreSettore sanitario

5.12 -2.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

5.11

Massimo

5.16

Metriche Chiave
By Trading Economics
Entrata	-2.7M -32M
Dipendenti	70
EBITDA	-3.9M -33M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+114.84% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-47M 1.1B
Apertura precedente	7.22
Chiusura precedente	5.12

Notizie sul Sentiment di mercato

By Acuity

46%

54%

145 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

2.76 / 2.84 Supporto e resistenza

Savara Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 mag 2026, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 mag 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 mag 2026, 18:37 UTC

I principali Market Mover

Senseonic Shares Slide on Underwritten Offering Price

1 mag 2026, 16:46 UTC

I principali Market Mover

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 mag 2026, 19:57 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 mag 2026, 15:24 UTC

Utili

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 mag 2026, 12:46 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 mag 2026, 08:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

1 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 mag 2026, 20:42 UTC

Utili

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

1 mag 2026, 19:33 UTC

Discorsi di Mercato

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 mag 2026, 19:18 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 mag 2026, 19:13 UTC

Discorsi di Mercato

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 mag 2026, 18:36 UTC

Utili

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 mag 2026, 18:35 UTC

Utili

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mag 2026, 18:28 UTC

Utili

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 mag 2026, 18:27 UTC

Discorsi di Mercato

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 mag 2026, 18:14 UTC

Acquisizioni, Fusioni, Takeovers

Barclays Completes Acquisition of Best Egg

1 mag 2026, 18:04 UTC

Utili

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 mag 2026, 17:43 UTC

Discorsi di Mercato

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 mag 2026, 17:37 UTC

Discorsi di Mercato

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 mag 2026, 17:30 UTC

Discorsi di Mercato

Utili

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 mag 2026, 17:28 UTC

Discorsi di Mercato

Utili

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 mag 2026, 17:21 UTC

Discorsi di Mercato

Utili

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 mag 2026, 17:19 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 mag 2026, 16:38 UTC

Discorsi di Mercato

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 mag 2026, 16:23 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Savara Inc Previsione

Obiettivo di Prezzo

By TipRanks

114.84% in crescita

Previsioni per 12 mesi

Media 11 USD 114.84%

Alto 16 USD

Basso 9 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Savara Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Savara Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

2.76 / 2.84Supporto e resistenza

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

145 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.